Patents Assigned to Acumen Pharmaceuticals, Inc.
-
Patent number: 9320793Abstract: This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.Type: GrantFiled: December 4, 2012Date of Patent: April 26, 2016Assignees: Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.Inventors: William F. Goure, Franz F. Hefti, Renee C. Gaspar, Paul J. Shughrue, Fubao Wang, Weirong Wang, Ningyan Zhang, Wei-Qin Zhao, Alexander McCampbell, Min Xu
-
Patent number: 9310383Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.Type: GrantFiled: June 3, 2015Date of Patent: April 12, 2016Assignees: Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Ningyan Zhang, Wei-Qin Zhao, Min Xu
-
Patent number: 9217024Abstract: This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.Type: GrantFiled: December 17, 2008Date of Patent: December 22, 2015Assignee: Acumen Pharmaceuticals, Inc.Inventors: Jasna Jerecic, Grant A. Krafft
-
Patent number: 9176151Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.Type: GrantFiled: July 9, 2012Date of Patent: November 3, 2015Assignee: Acumen Pharmaceuticals, Inc.Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Nigyan Zhang, Wei-Qin Zhao
-
Patent number: 9006283Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers.Type: GrantFiled: July 12, 2007Date of Patent: April 14, 2015Assignee: Acumen Pharmaceuticals, Inc.Inventors: Grant A. Krafft, Todd Pray, William F. Goure
-
Patent number: 8962677Abstract: Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A?1-42 monomers.Type: GrantFiled: July 12, 2007Date of Patent: February 24, 2015Assignee: Acumen Pharmaceuticals, Inc.Inventors: Grant A. Krafft, Todd Pray, William F. Goure
-
Publication number: 20130330837Abstract: Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid ? (Abeta) and methods utilizing such antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.Type: ApplicationFiled: July 16, 2013Publication date: December 12, 2013Applicants: Acumen Pharmaceuticals, Inc., Northwestern UniversityInventors: Mary P. Lambert, Pauline T. Velasco, Lei Chang, Kirsten L. Viola, Sara J. Fernandez, Pascale N. Lacor, Daliya Khuon, Yuesong Gong, William L. Klein, Grant A. Krafft
-
Patent number: 8507206Abstract: Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid ? (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.Type: GrantFiled: July 5, 2005Date of Patent: August 13, 2013Assignees: Northwestern University, Acumen Pharmaceuticals, Inc.Inventors: Mary P Lambert, Pauline T. Velasco, Lei Chang, Kirsten L. Viola, Sara J. Fernandez, Pascale N. Lacor, Daliya Khuon, Yuesong Gong, William L. Klein, Grant A. Krafft
-
Publication number: 20130089537Abstract: This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.Type: ApplicationFiled: December 4, 2012Publication date: April 11, 2013Applicants: MERCK SHARP & DOHME CORP., ACUMEN PHARMACEUTICALS, INC.Inventors: Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.
-
Publication number: 20130078269Abstract: The present invention provides amyloid ? peptide assemblies composed of at least three amyloid ? peptide subunits, wherein at least one of the amyloid ? peptide subunits is an amyloid ? peptide analog. The invention further relates to metal complexes of amyloid ? peptide assemblies and the use of amyloid ? peptide assemblies as vaccines and in the identification of agents that modulate assembly of the amyloid ? peptide subunits.Type: ApplicationFiled: November 14, 2012Publication date: March 28, 2013Applicants: ACUMEN PHARMACEUTICALS, INC., NORTHWESTERN UNIVERSITYInventors: Northwestern University, Acumen Pharmaceuticals, Inc.
-
Patent number: 7964359Abstract: The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric A? peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric A? peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric A? peptide assemblies, also known as ADDLs, and ADDL-related assemblies.Type: GrantFiled: May 11, 2007Date of Patent: June 21, 2011Assignees: Acumen Pharmaceuticals, Inc., Northwestern UniversityInventors: Wei-Qin Zhao, Grant A. Krafft, William L. Klein
-
METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS
Publication number: 20110098309Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers using acylhydrazide compounds.Type: ApplicationFiled: July 11, 2008Publication date: April 28, 2011Applicant: ACUMEN PHARMACEUTICALS, INC.Inventors: Gary Charles Look, Lauri Schultz, Alexandre Mikhaylovich Polozov, Nikhil Bhagat, Jian Wang, David E. Zembower, William F. Goure, Todd Pray, Grant A. Krafft